Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux

Table 1 16-wk primary and secondary outcome measures of antireflux therapy (mean ± SD)

Variable	Baseline		16 wk therapy
	Antireflux therapy	Placebo	Antireflux therapy	Placebo
Age, yr	51.49 ± 9.83	51.48 ± 9.79
Sex, % Male	68.7	68.7
Female	31.3	31.3
BMI, kg/m2	27.33 ± 1.93	27.37 ± 1.96
Asthma symptom score
Daytime	2.48 ± 0.80	2.46 ± 0.79	2.04 ± 0.68)b	2.24 (0.64)
Nighttime	2.60 ± 0.80	2.59 ± 0.79	2.09 ± 0.67b	2.45 (0.71)
Reflux symptom score	2.48 ± 0.76	2.49 ± 0.73	1.52 ± 0.52b	2.45 (0.64)
Albuterol use,
number of puffs/week	3.27 ± 1.04	3.25 ± 1.02	2.51 ± 0.69b	3.15 (0.97)
PEFR, L/min
Morning	283.58 ± 43.27	285.45 ± 44.27	306.36 ± 42.19b	286.01 (43.89)
Evening	283.69 ± 54.49	288.06 ± 57.38	311.45 ± 50.85b	286.63 (53.39)
FEV1
L	1.89 ± 0.40	1.85 ± 0.40	2.10 ± 0.34b	1.92 (0.41)
% predicted	68.58 ± 3.56	68.69 ± 3.59	70.66 ± 3.02b	68.89 (3.57)
FVC
L	1.94 ± 0.37	1.97 ± 0.35	2.12 ± 0.31b	1.94 (0.37)
% predicted	69.24 ± 3.39	69.65 ± 3.45	71.12 ± 2.88b	69.28 (3.42)

^bP < 0.01 vs Baseline, BMI: Body mass index; PEFR: Peak expiratory flow rate; FEV1: Forced vital capacity in 1 s; FVC: Forced vital capacity.